SCHEMBL2337573

SCHEMBL2337573

CNC(=O)C(C)NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
MMP2 P08253 5/20 0.55
MMP1 P03956 3/20 0.55
MMP9 P14780 3/20 0.55
MMP13 P45452 3/20 0.55
MMP3 P08254 2/20 0.55
MMP7 P09237 2/20 0.55
CA2 P00918 3/20 0.53
CA12 O43570 2/20 0.53
CA9 Q16790 2/20 0.53
CA14 Q9ULX7 2/20 0.53
CA1 P00915 2/20 0.53
CA3 P07451 1/20 0.53
CA4 P22748 1/20 0.53
CA6 P23280 1/20 0.53
CA5A P35218 1/20 0.53
CA7 P43166 1/20 0.53
CA13 Q8N1Q1 1/20 0.53
CA5B Q9Y2D0 1/20 0.53
HSD17B10 Q99714 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2339383 1.00 ALDH1A1 (0.56) ALDH1A1MMP2MMP1MMP9MMP13
SCHEMBL11704375 0.86 MMP2 (0.54) ALDH1A1MMP2MMP1MMP9MMP13
SCHEMBL11704368 0.86 MMP2 (0.54) ALDH1A1MMP2MMP1MMP9MMP13
SCHEMBL22500826 0.85 HSD17B10 (0.62) ALDH1A1MMP2MMP1MMP9MMP13
SCHEMBL4380323 0.83 ADAMTS4 (0.69) MMP2MMP1MMP9MMP13MMP3
SCHEMBL3884127 0.83 MMP2 (0.57) ALDH1A1MMP2MMP1MMP9MMP13
SCHEMBL3884130 0.83 MMP2 (0.57) ALDH1A1MMP2MMP1MMP9MMP13
SCHEMBL13890464 0.83 MMP2 (0.57) ALDH1A1MMP2MMP1MMP9MMP13
SCHEMBL3951681 0.83 ADAMTS4 (0.69) MMP2MMP1MMP9MMP13MMP3
SCHEMBL3951678 0.83 ADAMTS4 (0.69) MMP2MMP1MMP9MMP13MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US claimed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US claimed
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US disclosed
US-8193389-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
EP-2374792-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-10-12 EP disclosed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP disclosed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245573-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE ALDH1A1 665/4885MMP2 4105/4885MMP1 4462/4885
US-20120270902-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE ALDH1A1 665/4885MMP2 4105/4885MMP1 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.